Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 147
Filtrar
1.
Br J Pharmacol ; 177(13): 2889-2903, 2020 07.
Artículo en Inglés | MEDLINE | ID: mdl-32335915

RESUMEN

Immune checkpoint inhibitors have revolutionized cancer therapy leading to exceptional success. However, there is still the need to improve their efficacy in non-responder patients. Natural killer (NK) cells represent the first line of defence against tumours, due to their ability to release immunomodulatory cytokines and kill target cells that have undergone malignant transformation. Harnessing NK cell response will open new possibilities to improve control of tumour growth. In this respect inhibitory checkpoints expressed on these innate lymphocytes represents a promising target for next-generation immunotherapy. In this review, we will summarize recent evidences on the expression of NK cells receptors in cancer, with a focus on the inhibitory checkpoint programmed cell death protein 1 (PD-1). We will also highlight the strength and limitations of the blockade of PD-1 inhibitory pathway and suggest new combination strategies that may help to unleash more efficiently NK cell anti-tumour response.


Asunto(s)
Células Asesinas Naturales , Neoplasias , Humanos , Inmunoterapia , Neoplasias/tratamiento farmacológico
2.
New Phytol ; 196(3): 937-944, 2012 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-22943455

RESUMEN

Pollen is among the most ubiquitous of terrestrial fossils, preserving an extended record of vegetation change. However, this temporal continuity comes with a taxonomic tradeoff. Analytical methods that improve the taxonomic precision of pollen identifications would expand the research questions that could be addressed by pollen, in fields such as paleoecology, paleoclimatology, biostratigraphy, melissopalynology, and forensics. We developed a supervised, layered, instance-based machine-learning classification system that uses leave-one-out bias optimization and discriminates among small variations in pollen shape, size, and texture. We tested our system on black and white spruce, two paleoclimatically significant taxa in the North American Quaternary. We achieved > 93% grain-to-grain classification accuracies in a series of experiments with both fossil and reference material. More significantly, when applied to Quaternary samples, the learning system was able to replicate the count proportions of a human expert (R(2) = 0.78, P = 0.007), with one key difference - the machine achieved these ratios by including larger numbers of grains with low-confidence identifications. Our results demonstrate the capability of machine-learning systems to solve the most challenging palynological classification problem, the discrimination of congeneric species, extending the capabilities of the pollen analyst and improving the taxonomic resolution of the palynological record.


Asunto(s)
Inteligencia Artificial , Fósiles , Picea/fisiología , Polen/clasificación , Programas Informáticos , Procesamiento de Imagen Asistido por Computador/métodos , Internet , Picea/anatomía & histología , Polen/anatomía & histología , Polen/fisiología , Reproducibilidad de los Resultados
3.
Neuroscience ; 172: 219-25, 2011 Jan 13.
Artículo en Inglés | MEDLINE | ID: mdl-21056088

RESUMEN

Increasing evidence suggests that plastic changes underlying skill learning may occur at early stages of neural processing. However, whether visual perceptual learning (PL) is accompanied by neuronal plasticity phenomena in the primary visual cortex (V1) is yet unknown. Here, we provide the first evidence that practice with specific visual stimuli (gratings) induces long-term potentiation (LTP) of synaptic responses in the rat V1. We report that in rats which have improved through practice their ability to discriminate between two gratings of different spatial frequency, the input/output curves of field potentials evoked in layers II-III of V1 slices by stimulation of either vertical and horizontal connections are shifted leftward compared to controls. Thus, visual PL is followed by potentiation of synaptic transmission both in vertical and horizontal connections (mimicry). We next show that this increase in intracortical connectivity gain is paralleled by LTP-like phenomena caused by the learning process: indeed, visual PL occludes further LTP (occlusion). Mimicry and occlusion are not present in the primary somatosensory cortex of rats trained with PL. These results demonstrate that LTP accompanies PL and highlight the notion that learning can occur at processing stages as early as the primary sensory cortices.


Asunto(s)
Aprendizaje/fisiología , Potenciación a Largo Plazo/fisiología , Corteza Visual/fisiología , Percepción Visual/fisiología , Animales , Electrofisiología/métodos , Técnicas de Cultivo de Órganos , Estimulación Luminosa/métodos , Ratas , Ratas Long-Evans
4.
J Immunol Methods ; 322(1-2): 128-36, 2007 Apr 30.
Artículo en Inglés | MEDLINE | ID: mdl-17331531

RESUMEN

A new method for isolation and characterization of peptides presented in the context of the nonclassical human leukocytes antigen (HLA) class I molecule HLA-E was developed. A combination of different chromatographic steps coupled with electrospray mass spectrometry allowed us to detect the presence of small amounts of a naturally processed human Cytomegalovirus (HCMV)-derived peptide isolated from the HEK-293T/HLA-E+/UL40+ transfected cells of from HELA cell line. The peptide sequence was confirmed by tandem mass spectrometry (MS/MS). This approach provides a versatile and sensitive method for direct identification of MHC class I-binding peptides that might be derive from different pathogen or tumor-associated proteins.


Asunto(s)
Cromatografía Líquida de Alta Presión/métodos , Antígenos HLA/inmunología , Antígenos de Histocompatibilidad Clase I/inmunología , Espectrometría de Masas/métodos , Péptidos/inmunología , Péptidos/aislamiento & purificación , Secuencia de Aminoácidos , Membrana Celular/química , Células Cultivadas , Citomegalovirus , Antígenos HLA/química , Células HeLa , Antígenos de Histocompatibilidad Clase I/química , Humanos , Datos de Secuencia Molecular , Péptidos/química , Sensibilidad y Especificidad , Espectrometría de Masas en Tándem , Transfección , Antígenos HLA-E
5.
BMC Cancer ; 4: 46, 2004 Aug 09.
Artículo en Inglés | MEDLINE | ID: mdl-15301691

RESUMEN

BACKGROUND: We studied the expression of DMBT1 (deleted in malignant brain tumor 1), a putative tumor suppressor gene, in normal, proliferative, and malignant breast epithelium and its possible relation to cell cycle. METHODS: Sections from 17 benign lesions and 55 carcinomas were immunostained with anti DMBT1 antibody (DMBTh12) and sections from 36 samples, were double-stained also with anti MCM5, one of the 6 pre-replicative complex proteins with cell proliferation-licensing functions. DMBT1 gene expression at mRNA level was assessed by RT-PCR in frozen tissues samples from 39 patients. RESULTS: Normal glands and hyperplastic epithelium in benign lesions displayed a luminal polarized DMBTh12 immunoreactivity. Normal and hyperplastic epithelium adjacent to carcinomas showed a loss of polarization, with immunostaining present in basal and perinuclear cytoplasmic compartments. DMBT1 protein expression was down-regulated in the cancerous lesions compared to the normal and/or hyperplastic epithelium adjacent to carcinomas (3/55 positive carcinomas versus 33/42 positive normal/hyperplastic epithelia; p = 0.0001). In 72% of cases RT-PCR confirmed immunohistochemical results. Most of normal and hyperplastic mammary cells positive with DMBTh12 were also MCM5-positive. CONCLUSIONS: The redistribution and up-regulation of DMBT1 in normal and hyperplastic tissues flanking malignant tumours and its down-regulation in carcinomas suggests a potential role in breast cancer. Moreover, the concomitant expression of DMTB1 and MCM5 suggests its possible association with the cell-cycle regulation.


Asunto(s)
Aglutininas/metabolismo , Neoplasias de la Mama/genética , Carcinoma/genética , Receptores de Superficie Celular/metabolismo , Mama/patología , Neoplasias de la Mama/patología , Proteínas de Unión al Calcio , Carcinoma/patología , Ciclo Celular/genética , Proteínas de Ciclo Celular/metabolismo , Línea Celular Tumoral , Citoplasma/metabolismo , Citoplasma/patología , Proteínas de Unión al ADN , Regulación hacia Abajo , Epitelio/patología , Humanos , Hiperplasia/genética , Hiperplasia/patología , Inmunohistoquímica , ARN Mensajero/análisis , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Proteínas Supresoras de Tumor
6.
Arch Pathol Lab Med ; 125(12): 1588-90, 2001 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-11735696

RESUMEN

Clear cell mesothelioma is an extremely rare neoplasm of the pleura, which can easily be mistaken for a metastasis of clear cell carcinoma to the pleura. We report here the histochemical, immunohistochemical, and ultrastructural aspects of a new case of clear cell pleural mesothelioma in a 52-year-old man with no known asbestos exposure. He was admitted to the hospital for recurrent pleural effusion, which was negative for neoplastic cells at the cytologic examination. A partial decortication of the right pleura was performed. The morphologic, immunohistochemical, and ultrastructural features reported for this case are consistent with the diagnosis of clear cell mesothelioma. The differential diagnosis and immunohistochemical features in comparison with other clear cell neoplasms are discussed.


Asunto(s)
Células Epitelioides/patología , Mesotelioma/patología , Neoplasias Pleurales/patología , Biomarcadores de Tumor/análisis , Calbindina 2 , Desmosomas/ultraestructura , Diagnóstico Diferencial , Células Epitelioides/química , Resultado Fatal , Humanos , Técnicas para Inmunoenzimas , Masculino , Mesotelioma/química , Mesotelioma/cirugía , Microscopía Electrónica , Microvellosidades/ultraestructura , Persona de Mediana Edad , Derrame Pleural Maligno/etiología , Derrame Pleural Maligno/patología , Neoplasias Pleurales/química , Neoplasias Pleurales/cirugía , Proteína G de Unión al Calcio S100/análisis
7.
Eur J Immunol ; 31(12): 3687-93, 2001 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-11745389

RESUMEN

Cytolytic T lymphocytes (CTL) are known to recognize antigen peptides in association with major histocompatibility complex (MHC) class I molecules expressed on target cells. However, a fraction of human CD8(+) CTL has been shown to lyse certain natural killer (NK)-susceptible target cells via still undefined mechanism(s). These CD8(+) T cells, hereafter referred to as NK-CTL, are frequently composed of cells expressing one single TCR Vbeta expansion (different in different individuals), display a memory phenotype and express HLA class I-specific inhibitory NK receptors. Here we show that cell populations or clones of NK-CTL isolated from three healthy donors homogeneously expressed Vbeta16, Vbeta9 and Vbeta3 TCR, respectively. Various clones isolated under limiting dilution conditions from Vbeta16(+) cells of donor 1 displayed identical TCR Vbeta and Valpha rearrangements, thus suggesting a substantial monoclonality of the NK-CTL subset analyzed. NK-CTL lysed a number of NK-susceptible tumor target cells with the exception of those characterized by beta2-microglobulin (beta2m) deficiency. However, the latter targets became susceptible to lysis upon beta2m transfection. Using monoclonal antibodies specific for the relevant TCR Vbeta or beta2m we provide evidence suggesting that target cell lysis by NK-CTL is mediated by the TCR itself upon recognition of beta2m-associated proteins. The cellular distribution of the potential beta2m-associated proteins in susceptible target cells suggested, as a likely candidate for TCR-mediated recognition, the non-classical HLA-E molecule. The use, as target cells, of the murine TAP2-deficient RMA-S cells, either untransfected or transfected with HLA-E, and loaded with an appropriate HLA-E-binding peptide, provided the direct demonstration that HLA-E represents a ligand recognized by the TCR expressed by NK-CTL. This is the first evidence that human TCR alpha/beta can recognize HLA-E molecules, thus revealing a novel type of TCR-mediated recognition, which may offer new insight in immune responses in both normal and disease conditions.


Asunto(s)
Antígenos HLA/fisiología , Antígenos de Histocompatibilidad Clase I/fisiología , Células Asesinas Naturales/inmunología , Receptores de Antígenos de Linfocitos T alfa-beta/fisiología , Linfocitos T Citotóxicos/inmunología , Células Cultivadas , Citotoxicidad Inmunológica , Humanos , Microglobulina beta-2/fisiología , Antígenos HLA-E
8.
Am J Clin Pathol ; 116(5): 721-8, 2001 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-11710690

RESUMEN

We studied the presence of surfactant protein A (Sp-A) immunoreactivity and messenger RNA in 62 normal and abnormal breast samples. Sections were immunostained with polyclonal anti-Sp-A antibody. The association between Sp-A immunoreactivity and histologic grade of 32 invasive ductal carcinomas was assessed by 3 pathologists who scored the intensity of Sp-A immunoreactivity times the percentage of tumor immunostained; individual scores were averaged, and the final scores were correlated with tumor grade, proliferative index, and expression of estrogen and progesterone receptors. Strong Sp-A immunoreactivity was present at the luminal surface of ductal epithelial cells in normal breast samples and in benign lesions; carcinomas displayed variable immunoreactivity, inversely proportional to the degree of differentiation. Sp-A messenger RNA was detected by reverse transcriptase-polymerase chain reaction in 3 of 3 normal breast samples and 9 of 9 carcinomas. The significance of Sp-A expression in breast epithelium requires further study; possibly it has a role in native host defense or epithelial differentiation.


Asunto(s)
Neoplasias de la Mama/metabolismo , Mama/metabolismo , Carcinoma Intraductal no Infiltrante/metabolismo , Proteolípidos/biosíntesis , Surfactantes Pulmonares/biosíntesis , Mama/anatomía & histología , Mama/química , Mama/patología , Neoplasias de la Mama/química , Neoplasias de la Mama/patología , Carcinoma Intraductal no Infiltrante/química , Carcinoma Intraductal no Infiltrante/secundario , División Celular , Cartilla de ADN/química , Epitelio/química , Epitelio/metabolismo , Femenino , Humanos , Técnicas para Inmunoenzimas , Proteolípidos/análisis , Proteolípidos/genética , Proteína A Asociada a Surfactante Pulmonar , Proteínas Asociadas a Surfactante Pulmonar , Surfactantes Pulmonares/análisis , Surfactantes Pulmonares/genética , ARN Mensajero/metabolismo , ARN Neoplásico/análisis , Receptores de Estrógenos/análisis , Receptores de Estrógenos/metabolismo , Receptores de Progesterona/análisis , Receptores de Progesterona/metabolismo , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa
9.
Cancer Res ; 61(22): 8218-26, 2001 Nov 15.
Artículo en Inglés | MEDLINE | ID: mdl-11719453

RESUMEN

In this study, we investigated whether maturation of monocyte-derived myeloid dendritic cells (DCs) is differentially affected by the uptake of dying human melanoma cells in distinct phases of apoptosis. Maturation of monocyte-derived DCs, as documented by phenotype analysis and T-cell immunostimulatory activity, was inhibited by phagocytosis of dying melanoma cells containing a large fraction of cells in early apoptosis (Annexin-V+ and propidium iodide-) but promoted by the same tumors when in late apoptosis/secondary necrosis (Annexin-V+ and propidium iodide+) or when dying by primary necrosis. These opposite effects on DC maturation were observed after the uptake of early or late apoptotic cells from most vertical growth phase primary tumors and all metastases but not after the uptake of dying cells from a radial growth phase primary tumor or normal adult melanocytes. Inhibition of DC maturation by early apoptotic melanoma cells correlated with expression of interleukin-10 in neoplastic cells and was prevented by preincubating the tumor cells with a neutralizing antibody to interleukin-10 before tumor uptake by DCs. Cross-presentation of the melanoma-associated antigen gp100(209-217) to peptide-specific CTLs by HLA-A*0201+ DCs was achieved 48-72 h after phagocytosis of HLA-A*0201- melanoma cells in apoptosis, or primary necrosis, but only when tumor necrosis factor-alpha was added to DCs 4 h after the initiation of tumor phagocytosis. These results suggest that phases of apoptosis and neoplastic transformation affect maturation of myeloid DCs that take up dying cells of the melanocyte lineage. However, neoplastic cells in late apoptosis, or even in primary necrosis, induce only a partial DC differentiation not sufficient to achieve cross-presentation of tumor antigens to CTLs unless further DC maturation is promoted by additional signals. These results suggest a novel mechanism of tumor escape that may prevent the development of antitumor immunity through the maturation block induced in DCs by neoplastic cells in the early phase of apoptosis.


Asunto(s)
Apoptosis/inmunología , Diferenciación Celular/inmunología , Células Dendríticas/inmunología , Melanocitos/inmunología , Melanoma/inmunología , Adulto , Presentación de Antígeno , Antígenos de Neoplasias/inmunología , Apoptosis/efectos de la radiación , Comunicación Celular/inmunología , Transformación Celular Neoplásica/inmunología , Transformación Celular Neoplásica/patología , Células Dendríticas/citología , Humanos , Interleucina-10/inmunología , Melanocitos/citología , Melanoma/patología , Necrosis , Transducción de Señal/inmunología , Linfocitos T Citotóxicos/inmunología , Rayos Ultravioleta
10.
Virchows Arch ; 439(2): 196-200, 2001 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-11561761

RESUMEN

Meningiomas are common, usually benign slow-growing neoplasms of the central nervous system thought to arise from meningocytes capping arachnoid villi. Primary ectopic meningiomas are exceedingly rare extracranial and extraspinal tumors of controversial origin; they are usually limited to the head and neck region or to the paravertebral soft tissues. Only one mediastinal ectopic meningioma and few pulmonary ectopic meningiomas have been described in the literature until now. Because of their rarity and their intriguing pathogenesis, we report here a second case of primary mediastinal meningioma and an additional case of primary pulmonary meningioma. Their possible origin and differential diagnosis are discussed.


Asunto(s)
Neoplasias Pulmonares/patología , Neoplasias del Mediastino/patología , Meningioma/patología , Biomarcadores de Tumor/análisis , Diagnóstico Diferencial , Femenino , Humanos , Técnicas para Inmunoenzimas , Neoplasias Pulmonares/química , Neoplasias Pulmonares/cirugía , Masculino , Neoplasias del Mediastino/química , Neoplasias del Mediastino/cirugía , Melanoma/diagnóstico , Melanoma/secundario , Meningioma/química , Meningioma/cirugía , Persona de Mediana Edad , Neoplasias de Tejido Muscular/diagnóstico , Neoplasias del Sistema Nervioso Periférico/diagnóstico , Resultado del Tratamiento
11.
Ann Oncol ; 12(4): 505-8, 2001 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-11398884

RESUMEN

BACKGROUND: The majority of high-dose chemotherapy (HDC)-related complications results from bone marrow aplasia, but the graft infusion per se may cause adverse reactions due to the injection of both dimethyl sulfoxide (DMSO) and cell lysis products. We evaluated the feasibility of a two-step chemotherapy regimen with peripheral blood progenitor cell (PBPC) support in association with a novel procedure to remove DMSO and products of cell lysis from the cryopreserved cells. PATIENTS AND METHODS: Stage III and IV breast cancer patients received induction chemotherapy with three cycles of CEF (cyclophosphamide 600 mg/m2, epirubicin 100 mg/m2, 5-fluorouracil 600 mg/m2) followed by three cycles of HDC consisting of escalating doses of cyclophosphamide (dose range 1200 3000 mg/m2) and carboplatin (dose range 600-1000 mg/m2), supported by DMSO-free PBPC reinfusion. DMSO was removed by a washing/enzymatic digestion procedure. RESULTS: Twenty patients received induction chemotherapy and eighteen completed the entire chemotherapy program; a total of fifty-four cycles of HDC were administered. Dose limiting toxicity of HDC was long-lasting grade 4 neutropenia associated with documented infection. The maximum tolerated dose (MTD) was cyclophosphamide 3000 mg/m2 and carboplatin 600 mg/m2. No side effects related to PBPC reinfusion were observed. CONCLUSIONS: The proposed two-step chemotherapy regimen, associated with a novel washing/enzymatic digestion procedure, is feasible in advanced breast cancer patients in the absence of complications related to the specific toxicity of PBPC reinfusion.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias de la Mama/terapia , Carboplatino/uso terapéutico , Crioprotectores/metabolismo , Ciclofosfamida/uso terapéutico , Dimetilsulfóxido/metabolismo , Epirrubicina/uso terapéutico , Fluorouracilo/uso terapéutico , Factor Estimulante de Colonias de Granulocitos/uso terapéutico , Trasplante de Células Madre Hematopoyéticas/métodos , Adulto , Neoplasias de la Mama/mortalidad , Neoplasias de la Mama/secundario , Centrifugación , Terapia Combinada , Femenino , Filgrastim , Humanos , Persona de Mediana Edad , Estadificación de Neoplasias , Proteínas Recombinantes , Inducción de Remisión/métodos , Resultado del Tratamiento
12.
Lung Cancer ; 33(1): 27-39, 2001 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-11429193

RESUMEN

Integration of chemotherapy and radiation is the standard practice in the management of locally advanced inoperable NSCLC. To assess the biological interaction between third generation chemotherapeutic agents and radiation in non-small cell lung cancer (NSCLC) in vitro, we tested a number of different drugs (paclitaxel, docetaxel, gemcitabine, topotecan, SN-38 and cisplatin) combined with radiation, in lung cancer cell lines. Cellular chemosensitivity was determined, using the semi-automated colorimetric MTT assay, after 48, 72 and 96 h of exposure to increasing drug concentrations, (0.001-100 microM) and radiation doses (100-400 cGy). Cell lines used were the adenocarcinoma (ADK), A-549, and the squamous-cell carcinoma (SCC), LX-1. Cells were pre-treated with anticancer agents at 24, 12 and 0 h before irradiation. Cytofluorimetric cell cycle analysis was performed. A significant S-phase block or a G(2)/M block was seen with gemcitabine and topotecan or paclitaxel pre-treatment, respectively. Apoptosis was seen only after paclitaxel exposure in the A-549 cell line. Despite a similar pattern of cell-kinetic changes induced by chemotherapy pre-treatment in all cell lines, the adenocarcinoma A-549 cell line was not radiosensitized by any of the anticancer agents tested, whereas synergism was observed in the LX-1 squamous carcinoma cell line, when exposed to gemcitabine, SN-38, topotecan and cisplatin. Paclitaxel, despite a favourable cell cycle effect, was not found to be synergistic with radiotherapy in our experimental model. In conclusion, the observed synergism appears to be dose- and timing-independent and seems to be related to the histological subtype being present in SCC only. Favourable perturbation of the cell cycle is evident with all the new agents tested in both cell types, but was not sufficient to produce synergism with radiation.


Asunto(s)
Antineoplásicos/farmacología , Carcinoma de Pulmón de Células no Pequeñas/patología , Ciclo Celular/efectos de los fármacos , Ciclo Celular/efectos de la radiación , Neoplasias Pulmonares , Terapia Combinada , Humanos , Cinética , Radioterapia , Células Tumorales Cultivadas
13.
Am J Respir Cell Mol Biol ; 24(3): 253-63, 2001 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-11245624

RESUMEN

Rat surfactant protein (SP)-C is a 3.7-kD hydrophobic lung-specific protein generated from proteolytic processing of a 21-kD propeptide (SP-C(21)). We have demonstrated that initial post-translational processing of SP-C(21) involves two cleavages of the COOH-terminus (Beers and colleagues, J. Biol. Chem. 1994;269:20,318--20,328). The goal of the current study was to define processing and function of the NH(2)-terminal flanking domain. Epitope-specific antisera directed against spatially distinct regions of the NH(2) terminus, NPROSP-C(2-9) (epitope = D(2)-L(9)) and NPROSP-C(11-23) (= E(11)-Q(23)) were produced. By Western blotting, both antisera identified SP-C(21) in microsomes. A 6-kD form (SP-C(6)), enriched in lamellar bodies (LBs), was detected only by NPROSP-C(11-23) and not extractable with NaCO(3) treatment. Immunogold staining of ultrathin lung sections with NPROSP-C(11-23) identified proSP-C in both multivesicular bodies (mvb) and LBs whereas NPROSP-C(2-9) labeled only mvb. (35)S-pulse chase analysis demonstrated synthesis of SP-C(21) and three intermediate forms (SP-C(16), SP-C(7), and SP-C(6)). Complete processing involved four separate cleavages with a precursor- product relationship between the low molecular weight forms SP-C(7) and SP-C(6). Fluorescence microscopy of A549 cells expressing fusion proteins of enhanced green fluorescent protein (EGFP) and proSP-C NH(2)-terminal deletion mutants showed targeting of EGFP/SP-C(1-194) and EGFP/SP-C(10-194) to early endosomal antigen-1-negative, CD-63-positive cytoplasmic vesicles whereas EGFP/SP-C(19-194), EGFP/SP-C(Delta 10-18), and EGFP/SP-C(24-194) were restricted to the endoplasmic reticulum (ER). We conclude that synthetic processing includes a previously unrecognized cleavage of the proximal NH(2) terminus (M(1)-L(9)), which occurs after removal of COOH-flanking domains (H(59)-I(194)) but before packaging in LBs, and that the region M(10)-T(18) is required for targeting of proSP-C to post-ER vesicular compartments in the biosynthetic pathway.


Asunto(s)
Pulmón/metabolismo , Péptidos/metabolismo , Procesamiento Proteico-Postraduccional , Proteolípidos/metabolismo , Surfactantes Pulmonares/metabolismo , Secuencia de Aminoácidos , Animales , Línea Celular , Clonación Molecular , Cartilla de ADN , Epítopos , Proteínas Fluorescentes Verdes , Humanos , Proteínas Luminiscentes/análisis , Proteínas Luminiscentes/genética , Pulmón/citología , Pulmón/ultraestructura , Masculino , Microscopía Inmunoelectrónica , Mutagénesis Sitio-Dirigida , Péptidos/química , Reacción en Cadena de la Polimerasa , Biosíntesis de Proteínas , Proteolípidos/química , Proteolípidos/genética , Proteína C Asociada a Surfactante Pulmonar , Surfactantes Pulmonares/química , Surfactantes Pulmonares/genética , Ratas , Ratas Wistar , Proteínas Recombinantes de Fusión/biosíntesis , Alineación de Secuencia , Homología de Secuencia de Aminoácido , Transfección
14.
J Med Virol ; 62(3): 354-63, 2000 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-11055246

RESUMEN

Natural killer (NK) cells have the capability of lysing targets that have down-regulated the expression of HLA class I molecules. Herpes simplex virus (HSV) infection results in a profound reduction of HLA class I molecules on the surface of infected cells. For this reason, NK cell populations kill efficiently HSV-infected cells. The recent availability of a panel of monoclonal antibodies directed to NK receptors for HLA class I (CD158a, CD158b, anti-p70, anti-p140, and CD94) allowed an accurate dissection of the NK cell subpopulations. Using this approach, the relationship between the expression of NK cell receptors and the capability of lysing HSV-infected cell targets was analyzed at the clonal level. NK cell clones were derived from healthy donors, and cytolytic properties were assayed against HSV-infected autologous fibroblasts. NK cell clones, classified according to the expression of natural killer-cell receptors on their surface, displayed a great heterogeneity of cytolytic properties against HSV-infected cells. Nevertheless, a more accurate functional analysis demonstrated not only that HSV infection downregulated the expression of HLA-A and HLA-B and did not modify the expression of HLA-C, but also that NK cell clones expressing the "activating" form of the anti HLA-C NK cell receptor were more cytolytic than other clones. This finding suggests that two different and clonally distributed mechanisms of NK cell activation may be employed by NK cells to kill HSV-infected autologous target cells.


Asunto(s)
Células Asesinas Naturales/inmunología , Simplexvirus/inmunología , Células Cultivadas , Células Clonales , Citotoxicidad Inmunológica , Fibroblastos , Fluorescencia , Antígenos HLA-A/análisis , Antígenos HLA-B/análisis , Antígenos HLA-C/análisis , Humanos , Inmunidad Celular , Células Asesinas Naturales/metabolismo , Activación de Linfocitos , Receptores Inmunológicos/metabolismo
15.
Virchows Arch ; 436(3): 289-95, 2000 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-10782889

RESUMEN

Peripheral papillary adenomas of the lung are uncommon neoplasms (only ten cases have been described so far in the English literature) composed predominantly of type-II pneumocytes and generally considered benign. We describe here two additional cases of this lung tumor. In both cases histological examination revealed an encapsulated papillary neoplasm with invasion of the capsule and, in one case, invasion of the adjacent alveoli and visceral pleura too. The proliferative index (Ki67) was less than 2% and the epithelial cells were positive for cytokeratins, surfactant apoproteins (SP), and nuclear thyroid transcription factor-1 (TTF- 1). Ultrastructurally, the epithelial cells showed the characteristic surface microvilli and cytoplasmic lamellar inclusions of type-II cells. Review of the literature has revealed two other cases of peripheral papillary adenoma of type-II pneumocytes with infiltrative features. Thus, we propose replacing the term peripheral papillary adenoma with peripheral papillary tumor of undetermined malignant potential.


Asunto(s)
Adenoma/patología , Neoplasias Pulmonares/patología , Adenoma/fisiopatología , Adenoma/cirugía , Adolescente , Adulto , Humanos , Pulmón/patología , Pulmón/ultraestructura , Neoplasias Pulmonares/fisiopatología , Neoplasias Pulmonares/cirugía , Masculino , Microscopía Electrónica
16.
Tissue Antigens ; 55(3): 212-8, 2000 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-10777096

RESUMEN

Interferons upregulate the expression of HLA class I antigens on cancer cells. Nevertheless, little is known about the panel of HLA class I antigen-associated peptides presented by recombinant alpha-interferon (r(alpha)-IFN)-treated cells. For this reason, peptides were eluted from five cancer cell lines (four melanoma and one non-small cell lung cancer) following treatment with r(alpha)-IFN. High-performance liquid chromatography (HPLC) profiles of the peptide fractions were compared with those obtained from untreated cells. No significant differences in peptide characteristics (detectable on the basis of retention times) were observed, but significant differences in terms of peptide quantities were observed. Mass spectrometry performed on HPLC peaks allowed not only the detection of three different peptides (two derived from the MAGE family of genes and one from the mart-1) both in untreated and in treated cells, but also gave an indication of the number of peptides within one HPLC peak. This data demonstrates that r(alpha)-IFN-treated cells express a similar peptide pattern as untreated cells, with significant quantitative differences. Interestingly, this finding also explains the higher susceptibility to lysis (mediated by specific cytolytic lymphocytes, which recognize cancer cells in an HLA-restricted fashion) of r(alpha)-IFN-treated cells.


Asunto(s)
Antígenos de Histocompatibilidad Clase I/metabolismo , Interferón-alfa/farmacología , Péptidos/metabolismo , Antígenos de Neoplasias/metabolismo , Antígenos HLA-A/metabolismo , Antígenos HLA-B/metabolismo , Humanos , Células K562 , Antígeno MART-1 , Antígenos Específicos del Melanoma , Proteínas de Neoplasias/metabolismo , Células Tumorales Cultivadas
17.
Am J Physiol Lung Cell Mol Physiol ; 278(4): L794-805, 2000 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-10749757

RESUMEN

Vascular immunotargeting is a novel approach for site-selective drug delivery to endothelium. To validate the strategy, we conjugated glucose oxidase (GOX) via streptavidin with antibodies to the endothelial cell surface antigen platelet endothelial cell adhesion molecule (PECAM). Previous work documented that 1) anti-PECAM-streptavidin carrier accumulates in the lungs after intravenous injection in animals and 2) anti-PECAM-GOX binds to, enters, and kills endothelium via intracellular H(2)O(2) generation in cell culture. In the present work, we studied the targeting and effect of anti-PECAM-GOX in animals. Anti-PECAM-GOX, but not IgG-GOX, accumulated in the isolated rat lungs, produced H(2)O(2,) and caused endothelial injury manifested by a fourfold elevation of angiotensin-converting enzyme activity in the perfusate. In intact mice, anti-PECAM-GOX accumulated in the lungs (27 +/- 9 vs. 2.4 +/- 0.3% injected dose/g for IgG-GOX) and caused severe lung injury and 95% lethality within hours after intravenous injection. Endothelial disruption and blebbing, elevated lung wet-to-dry ratio, and interstitial and alveolar edema indicated that anti-PECAM-GOX damaged pulmonary endothelium. The vascular injury in the lungs was associated with positive immunostaining for iPF(2alpha)-III isoprostane, a marker for oxidative stress. In contrast, IgG-GOX caused a minor lung injury and little (5%) lethality. Anti-PECAM conjugated with inert proteins induced no death or lung injury. None of the conjugates caused major injury to other internal organs. These results indicate that an immunotargeting strategy can deliver an active enzyme to selected target cells in intact animals. Anti-PECAM-GOX provides a novel model of oxidative injury to the pulmonary endothelium in vivo.


Asunto(s)
Endotelio Vascular/enzimología , Marcación de Gen , Glucosa Oxidasa/genética , Estrés Oxidativo , Circulación Pulmonar , Enfermedades Vasculares/inducido químicamente , Animales , Anticuerpos/genética , Anticuerpos/inmunología , Anticuerpos/metabolismo , Anticuerpos/farmacología , Glucosa Oxidasa/inmunología , Glucosa Oxidasa/metabolismo , Técnicas In Vitro , Enfermedades Pulmonares/inducido químicamente , Enfermedades Pulmonares/patología , Ratones , Molécula-1 de Adhesión Celular Endotelial de Plaqueta/inmunología , Ratas , Distribución Tisular , Enfermedades Vasculares/patología
18.
Pathologica ; 92(6): 496-502, 2000 Dec.
Artículo en Italiano | MEDLINE | ID: mdl-11234300

RESUMEN

Aim of this work was to investigate the ability of the antibodies against Surfactant proteins (SP) and Thyroid transcription factor 1 (TTF-1) to distinguish primary neoplasms of the lung from metastatic carcinomas to the lung and pleural mesotheliomas. We evaluated the immunohistochemical expression of the antibodies anti SP-A, SP-B, pro SP-C, SP-D, and TTF-1 in a series of 56 primary lung carcinomas, 9 metastatic carcinomas to the lung, 5 pleural mesotheliomas and 8 non-pulmonary carcinomas. Among primary lung neoplasms, only adenocarcinomas immunostained for all SP (specificity = 1; total sensitivity = 0.52). TTF-1 had an excellent specificity (= 1), but a weak sensitivity (= 0.34) in recognizing primary lung carcinomas. TTF-1 was present in lung adenocarcinomas which were negative for SPs; however it failed to distinguish the subtypes. Pleural mesotheliomas, pulmonary metastases and non-pulmonary carcinomas were not immunoreactive for SP-A, SP-B, SP-D, and TTF-1. Pro SP-C was positive also in the adenocarcinomas of the large bowel and in their pulmonary and nodal metastases. These results demonstrate that the combined use of antibodies anti SP-A, SP-B and TTF-1 is the best association in distinguishing primary lung carcinomas from metastatic carcinomas to the lung and pleural mesotheliomas.


Asunto(s)
Biomarcadores de Tumor/análisis , Carcinoma/diagnóstico , Glicoproteínas/análisis , Técnicas para Inmunoenzimas , Neoplasias Pulmonares/diagnóstico , Mesotelioma/diagnóstico , Proteínas de Neoplasias/análisis , Proteínas Nucleares/análisis , Neoplasias Pleurales/diagnóstico , Proteolípidos/análisis , Surfactantes Pulmonares/análisis , Factores de Transcripción/análisis , Adenocarcinoma/química , Adenocarcinoma/diagnóstico , Adenocarcinoma/secundario , Carcinoma/química , Carcinoma/patología , Carcinoma/secundario , Neoplasias Colorrectales/química , Diagnóstico Diferencial , Humanos , Neoplasias Pulmonares/química , Neoplasias Pulmonares/patología , Neoplasias Pulmonares/secundario , Metástasis Linfática , Mesotelioma/química , Mesotelioma/patología , Neoplasias Pleurales/química , Neoplasias Pleurales/patología , Neoplasias Pleurales/secundario , Precursores de Proteínas/análisis , Proteína A Asociada a Surfactante Pulmonar , Proteína D Asociada a Surfactante Pulmonar , Proteínas Asociadas a Surfactante Pulmonar , Factor Nuclear Tiroideo 1
19.
Allergy ; 55(3): 226-31, 2000 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-10753012

RESUMEN

An in vitro flow cytometric model has been developed to evaluate the effects of antiallergic drugs such as cetirizine (CTZ) on the expression of surface molecules on primary cultured normal cells. Quantitative analysis demonstrated that HLA class I and ICAM-1/CD54 molecules are present on both epithelial and stromal cells, and that their expression is strongly enhanced by treatment with interferon-gamma (IFN-gamma). Nevertheless, the IFN-gamma-mediated upregulation of ICAM-1/CD54 was inhibited by treatment with CTZ, demonstrating a direct effect on both cell types. This finding is particularly interesting because ICAM-1/CD54 is the main rhinovirus receptor, and rhinoviruses are the principal cause of asthma exacerbation in children. Thus, according to data derived from this in vitro model, CTZ should have an important role in the reduction of infectious exacerbation of asthma in atopic patients.


Asunto(s)
Cetirizina/farmacología , Antagonistas de los Receptores Histamínicos H1/farmacología , Molécula 1 de Adhesión Intercelular/biosíntesis , Mucosa Nasal/efectos de los fármacos , Adulto , Células Cultivadas , Células Epiteliales/efectos de los fármacos , Células Epiteliales/metabolismo , Femenino , Fibroblastos/efectos de los fármacos , Fibroblastos/metabolismo , Citometría de Flujo/métodos , Antígenos de Histocompatibilidad Clase I/biosíntesis , Humanos , Interferón gamma/farmacología , Masculino , Persona de Mediana Edad , Mucosa Nasal/citología , Mucosa Nasal/metabolismo , Regulación hacia Arriba
20.
Ann Surg Oncol ; 6(3): 272-8, 1999.
Artículo en Inglés | MEDLINE | ID: mdl-10340886

RESUMEN

BACKGROUND: On the basis of our previous experience, we designed this study to determine the activity and toxicity of outpatient treatment with autologous tumor-infiltrating lymphocytes (TIL) together with intermediate-dose recombinant interleukin-2 (rIL-2) and low-dose recombinant interferon alfa-2a (rIFN-alpha2a), for patients with metastatic melanoma. METHODS: Between April 1992 and October 1994, we processed 38 melanoma samples derived from 36 patients with metastases. Proliferative cultures of expanded lymphocytes (TIL) were infused only once into patients with metastatic melanoma. rIL-2 was administered subcutaneously for 1 month, starting on the day of TIL infusion, at an escalating dose of 6-18 x 10(6) IU/m2/day for the first week and at the maximum-tolerated dose for the subsequent 3 weeks and then, after a 15-day interval, for 1 week/month for 3 months. rIFN-alpha2a was administered subcutaneously at 3 X 10(6) IU three times each week until progression. RESULTS: Of 38 melanoma samples, 19 (50%) resulted in proliferative cultures and were infused. The median number of expanded lymphocytes was 18 x 10(9) (range, 1-43 x 10(9)), and the median period of culture was 52 days (range, 45-60). rIL-2 was administered at doses ranging between 6 and 18 x 10(6) IU/m2/day. Toxicity was mild or moderate, and no life-threatening side effects were encountered. Two of 19 treated patients experienced complete responses of their metastatic sites (soft tissue), 10 had stable disease, and 7 showed progressive disease. The response rate was 11% (95% confidence interval, 2-35%). CONCLUSIONS: Outpatient treatment with TIL plus rIL-2 and rIFN-alpha2a is feasible, although, within the context of the small sample size, the activity of the combination was no different from the reported activity of any of the components used alone.


Asunto(s)
Inmunoterapia Adoptiva/métodos , Interferón-alfa/uso terapéutico , Interleucina-2/uso terapéutico , Linfocitos Infiltrantes de Tumor , Melanoma/terapia , Neoplasias Cutáneas/terapia , Adulto , Anciano , Quimioterapia Combinada , Femenino , Humanos , Interferón alfa-2 , Metástasis Linfática , Masculino , Melanoma/secundario , Persona de Mediana Edad , Proyectos Piloto , Proteínas Recombinantes
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA